Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Diagnostic and prognostic precision medicine for behavioral variant frontotemporal dementia

DIPPA-FTD

The behavioural variant of frontotemporal dementia (bvFTD) is a common cause of early-onset dementia that presents with changes in behavior and personality. It is often misdiagnosed and mistaken for a psychiatric disorder, such as depression or bipolar disorder. Unlike with Alzheimer’s disease, we still lack reliable tests that enable a diagnosis...

Funding Programme
Start Date
End Date
Total Funding
€ 1 320 000
European Countries Involved

Diagnostic Enhancement of Confidence by an International Distributed Environment

DECIDE

DECIDE (Diagnostic Enhancement of Confidence by an International Distributed Environment), aims at creating a e-Infrastructure to enhance the diagnostic confidence in chronic brain diseases such as Alzheimer and dementia. Proper management of these neurodegenerative diseases are thought to be very important in terms of health-economical point of...

Funding Programme
Start Date
End Date
Total Funding
€ 3 004 531
European Countries Involved

Dipeptide-Repeat Vaccine to prevent ALS and FTD in C9orf72 mutation carriers

DPR-VAX

Neurodegenerative diseases are triggered by protein aggregation in the CNS, but developing therapies has been challenging. Since key disease mechanisms change during disease progression, halting further neuron loss has not been achieved and may not even improve the symptoms and survival. Causal therapy is most realistic for monogenic disease...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Discovery and evaluation of novel butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease

BCHI FOR AD THERAPY

Alzheimer's disease (AD) is the most common neurodegenerative disorder and is incurable. A drug candidate specifically inhibiting butyrylcholinesterase (BChE) activity will lead to improved clinical outcome in the treatment of AD. The fellow Qiong Shen (QS) has extensive experience, knowledge and technical skills in research into AD. Previously she...

Funding Programme
Start Date
End Date
Total Funding
€ 169 958
European Countries Involved

Discovery of drugs for the treatment and prevention of Alzheimer's disease

ALZHEIMERSDRUG

Alzheimer’s disease is a neurodegenerative disease characterized by the accumulation of proteins and protein fragments in the brain, progressive neuronal loss, inflammation, and the gradual and inevitable decline of memory and cognition. Decline of memory and cognition is coupled with binding of β amyloid peptides (Aβ) and their derived diffusible...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Discovery of new Frontal Temporal Dementia multimodal spectral markers in biofluids.

IR4FTD

The central aim of the project is to apply multimodal spectroscopy combined with machine learning to identify a fingerprint for Frontal Temporal Dementia (FTD) and Alzheimer’s disease (AD) in saliva and plasma. FTD is the second most common dementia and usually affects individuals younger than 60 years old. FTD is difficult to diagnose, since there...

Funding Programme
Start Date
End Date
Total Funding
€ 287 152
European Countries Involved

Disentangling the contributions of dopamine and amyloid burden to age-related changes in cognition and brain network connectivity in healthy older adults

AMYDA

Normal aging is associated with declines in episodic memory and executive functions. Research suggests that around 20-50% of clinically healthy individuals show significant accumulation of amyloid, one of the hallmark biomarkers of Alzheimer’s disease but it has been difficult to establish the functional impact of amyloid burden in healthy older...

Funding Programme
Start Date
End Date
Total Funding
€ 258 766
European Countries Involved

Disrupting the Migraine continuum of care for resource constrained settings

TARA

Chronic migraine is defined as a headache persistent for more than 3 months or a severe headache persistent for more than 15 days within a month. It affects approximately 2% of the world population. The World Health Organization classifies severe migraine attacks as among the most disabling illnesses, comparable to dementia and quadriplegia...

Funding Programme
Start Date
End Date
Total Funding
€ 4 380 708
European Countries Involved

Disruptive Innovation to Treat Alzheimer’s and Parkinson’s diseases: new target, new patented drug, new therapeutic strategy.

AmInnovation

Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century. In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, and the number of cases will double before 2050. The current medical paradigms, which incriminate amyloid plaques as the...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Disruptive technologies for effectively rehabilitating chronic ambulatory disability

MARSI

Worlwide, about 60 million people have some kind of difficulty in walking, which is related to some neurological disorder (stroke, dementia, neuromuscular diseases, etc). Roughly 40 million of affected correspond to elders and the % is higher in Europe. The remaining is the sum of physically disabled by cerebral palsy (14 million), neuromuscular...

Funding Programme
Start Date
End Date
Total Funding
€ 2 499 150
European Countries Involved

Dissecting Alzheimer’s disease at a single molecule level

SINGLEMOLALZHEIMER

Fibrillar deposits of proteins are the hallmark of amyloid diseases, amongst which Alzheimer’s disease stands out as the most widespread neurodegenerative pathology of the brain. Neuronal dysfunction is currently attributed to the interaction of A-beta oligomers with the plasma membrane. Several scenarios have been proposed, but the mechanisms of...

Funding Programme
Start Date
End Date
Total Funding
€ 164 459
European Countries Involved

Dissecting Brain Pollutant Exposure and its Contribution to Neurodegeneration and Alzheimer’s disease: From Signatures to Prevention Strategies to Protect and Maintain a Healthy Brain

EXPOSIGNALZ

Human populations are impregnated by various types of chemical pollutants reported as hazardous waste present in the environment. Certain pollutants have adverse effects on brain, but the underlying mechanisms and time-window exposures are still unknown, as well as their contribution on dementia, the 7th leading cause of death. EXPOSIGNALZ project...

Funding Programme
Start Date
End Date
Total Funding
€ 930 987 982
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).